Given their extensive involvement in public procurement contracting, life sciences companies are likely to be heavily impacted by the EU’s Foreign Subsidies Regulation (the “FSR”), which has the potential to hold up tender awards over competition concerns. Michele Tagliaferri and Alessandra Moroni explain.
Stephen Abreu, Sidley partner, talks to Colin Hill, CEO and Co-Founder of AI-powered drug discovery company Aitia, about how the use of AI is revolutionizing the biotech space.
The original agreement for the UK’s withdrawal from the EU affected the availability of medicines in Northern Ireland and created issues for importers of medicinal products. The new ‘Windsor Framework’ is better for the industry, as Marie Manley and Bronwyn Tonelli explain.
The pharma industry was unhappy about a rule which prevented U.S. accountants and consultants, and even some in-house staff at pharma companies, from providing services to medical services companies in Russia. Carys Golesworthy explains how this has now changed.
Josh Hofheimer reports the takeaways from Sidley’s co-hosted pitch day with KoreaBio and BioCentury at the J.P. Morgan Healthcare Conference. The session included key insights on entrepreneurial developments and an investor panel on macroeconomic challenges.